Welt Elected as Director of the World DTx Association, First in Asia

Kim Ju-young, Head of US Corporation, Joins as DTA Director

World Digital Therapeutics Association (DTA) and Welt logos (from left) (Photo by DTA, Welt)

[Asia Economy Reporter Chunhee Lee] Digital therapeutics (DTx) company Welt has been elected as a board member of the global DTx Association (DTA), becoming the first in both Korea and Asia to achieve this.

According to Welt on the 10th, DTA announced on the 8th (local time) that Welt was selected as a board member for the upcoming year. The term is three years. This is the first time an Asian company has entered the DTA board.

DTA is a global DTx consortium with major members including global big pharma companies, digital therapeutics companies, and related organizations. About 15 companies, including Welt, participate from Korea. The board members of DTA include eight companies such as Welt, Pear Therapeutics, which developed the first FDA-approved DTx in the US, Akili Interactive, and Welldoc. Along with these companies and DTA Chairman Andy Molnar, a total of nine members will form the board.

Representing Welt, Danny Kim, head of the US branch, will join the DTA board. Newly appointed board member Danny Kim is a pharmacist who graduated from Northeastern University College of Pharmacy in Boston, USA, and has worked at digital healthcare-related companies such as online pharmacy startup PillPack and Pear Therapeutics in the US. Since joining Welt in 2020, he has been engaged in corporate development and has been serving as head of the US branch since March. Since last year, Kim has also been actively involved within DTA as co-chair of both the Asia-Pacific Policy Working Group and the Public Relations & Communications Working Group.

In particular, this election to the DTA board is considered a result that demonstrates the growth of the Korean and Asian DTx industries, as it was achieved just two years after Welt became the first Asian member of DTA in 2020. Since joining, Welt has served as the chair company leading the DTA Asia-Pacific branch. It also took the chair role at the ‘1st DTx Asia’ event held in Seoul on the 8th and 9th.

Andy Molnar, DTA Chairman, said, "We always work closely with the board to advance digital therapeutics," adding, "The DTA board members will play an important role as industry leaders in achieving clinical and economic outcomes of DTx."

Welt is developing 'PillowRx,' a CBT-based DTx for treating insomnia. PillowRx received approval for confirmatory clinical trials from the Ministry of Food and Drug Safety last September and is currently undergoing clinical trials.

This content was produced with the assistance of AI translation services.